Back to discover
Disease
Colon carcinoma
Late-stage therapeutic development
Also known as carcinoma of colon, carcinoma of the colon, colonic carcinoma, colon cancer.
19
Clinical trials
12
Associated genes
4
Related proteins
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Market withdrawal: Lextemy (EMA)
Regulatory2021-06-21EMA
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Moderate
Key developments
- 6 clinical trials expected to report results, the earliest in Q4 2026.
- 6 industry developments reported.
Upcoming Milestones
- Q4 2026A Randomized Trial of Microbiotic Product (NBT-NM108) to Promote Microbiome Health and Improve Chemotherapy Delivery
- Q1 2028A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy
- Q4 2028A Phase II Clinical Trial of Neoadjuvant Zanidatamab for HER2+ Localized Colorectal Cancer
- Q3 2029A Phase II Trial of Adjuvant Toripalimab in High Risk Localized Colon Cancer With Mismatch Repair Deficiency
- Q1 2032Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)
Major developments
Upcoming trial readoutHigh impact
Results expected Q2 20342026-07-02
Upcoming trial readoutImportant
Results expected Q4 20282026-04-17
Clinical MilestonesViewHide
Results posted
Results expected
- 2026-07-02Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon CancerResults expected Q2 2034
- 2026-04-17A Phase II Clinical Trial of Neoadjuvant Zanidatamab for HER2+ Localized Colorectal CancerResults expected Q4 2028
- 2026-03-05Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)Results expected Q1 2032
- 2026-01-06A Randomized Trial of Microbiotic Product (NBT-NM108) to Promote Microbiome Health and Improve Chemotherapy DeliveryResults expected Q4 2026
- 2025-12-05A Pilot Study to Evaluate the Benefits of Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral NeuropathyResults expected Q1 2028
Other updates
Industry & MarketView all 6Hide
- 2026-07-13Agenus scraps phase 3 colorectal study after 3 months to narrow focus to colon cancerTrial news · Fierce Biotech
- 2026-07-30How one amino acid might help fight colon cancer and infectionsIndustry · Science News
- 2026-07-16Scientists finally solved how a common gut bacterium triggers colon cancerIndustry · Science Daily
- 2026-04-22Hidden virus in your gut may be linked to colon cancerIndustry · ScienceDaily — Infectious Diseases
- 2026-04-02What’s hiding inside colon cancer could change treatmentIndustry · Science Daily
+1 more in the activity timeline below
Activity timeline14
- 2026-07-30IndustryHow one amino acid might help fight colon cancer and infectionsIndustry · Science News
- 2026-07-16IndustryScientists finally solved how a common gut bacterium triggers colon cancerIndustry · Science Daily
- 2026-07-13IndustryAgenus scraps phase 3 colorectal study after 3 months to narrow focus to colon cancerTrial news · Fierce Biotech
- 2026-07-02ClinicalRandomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon CancerResults expected Q2 2034
- 2026-04-22IndustryHidden virus in your gut may be linked to colon cancerIndustry · ScienceDaily — Infectious Diseases
- 2026-04-17ClinicalA Phase II Clinical Trial of Neoadjuvant Zanidatamab for HER2+ Localized Colorectal CancerResults expected Q4 2028
- 2026-04-02IndustryWhat’s hiding inside colon cancer could change treatmentIndustry · Science Daily
- 2026-03-25IndustryMost Americans don’t know this food raises colon cancer riskIndustry · Science Daily
- 2026-03-05ClinicalNeoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer (Amended Protocol of: Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL)Results expected Q1 2032
- 2026-02-10ClinicalS1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 AmplificationResults posted
Clinical trials
The current development programme across all trial phases.
Clinical programme
19
6
1
6
Recruiting
Recently completed
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
Safety updates
2021emaMarket withdrawal — Bevacizumab· Treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix. source ↗
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
Synonyms
carcinoma of colon, carcinoma of the colon, colonic carcinoma, colon cancer
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.